LG AI Research Unveils 'Cancer Agnostic AI' Capable of Designing Treatment in One Day

LG is pushing the boundaries of artificial intelligence, unveiling groundbreaking research in cancer treatment at the American Association for Cancer Research (AACR) conference in San Diego. Our "Cancer Agnostic AI," developed in collaboration with Vanderbilt University Medical Center, represents a significant leap forward in precision medicine.

This innovative AI system streamlines the entire process, from analyzing patient tissue samples to designing personalized treatment strategies, all within a remarkable 24-hour timeframe. At its core is "EXAONE Path," a pathology AI capable of predicting cancer gene activity from a single tissue image in under a minute. We've enhanced its prediction accuracy to world-class levels, promising to minimize unnecessary patient tests and identify those most likely to benefit from targeted therapies.

This advancement underscores LG's commitment to developing AI that transforms lives. By building the 'brain' for AI-driven precision cancer care, we are not just innovating in technology; we are offering new hope and more effective treatment pathways for cancer patients. This is a testament to our dedication to leveraging cutting-edge AI for the betterment of global health.